Melanoma

New Indication: Adjuvant Pembrolizumab for Melanoma

2022-05-20

  • Study

    Double-blind, randomised, phase 3 study (KEYNOTE-716)
    Newly diagnosed, completely resected stage IIB or IIC melanoma
    Pembrolizumab (n=483) or placebo (n=486)

  • Efficacy

    RFS : 20.9 mos: 85% vs. 76% [ HR: 0.61 (0·45–0·82)]
    mRFS not reached

  • Safety

    Grade >= 3 AEs: 16% vs 4%
    AEs related death: 0 vs 4 patients


    • Lancet. 2022 Apr 30;399(10336):1718-1729.

    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

    http://doi.org/10.1016/s0140-6736(22)00562-1

    Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022